Date: 2016-12-26
Type of information: Joint-venture agreement
Compound:
Company: Kubota Pharmaceutical (Japan) SBI Group (Japan)
Therapeutic area: Ophtalmological diseases
Type agreement: joint-venture
Action mechanism:
Disease:
Details: * On December 26, 2016, Kubota Pharmaceutical Holdings, a clinical-stage ophthalmology company and SBI Holdings, a financial services and asset management company based in Japan, announced the signing of a non-binding letter of intent to establish a joint venture that will organize and manage special purpose entities to finance the development of ophthalmic drugs and devices. The LOI contemplates that the joint venture will be funded 51% by Kubota Pharma and 49% by SBI. Kubota Pharma and SBI have entered negotiations for a definitive joint venture agreement. Concurrent with the negotiation of the definitive joint venture agreement, the parties intend to negotiate a separate definitive agreement to establish and fund the joint venture’s first special purpose entity, which is expected to be focused on mobile healthcare (mHealth) applications in the field of ophthalmology. In addition, through this first special purpose entity, Kubota Pharma will explore potential development and commercialization synergies between the mHealth platform and its drug product candidates already in development.
Financial terms:
Latest news:
